Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Rectal Cancer treatment details. Biologic therapy. Chemotherapy. Klinikum Muenchen-Grosshadern, MuŁnchen, Germany



Survival: 25.5 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: Germany
   
City/State/Province: MuŁnchen
   
Hospital: Klinikum Muenchen-Grosshadern
   
Journal: Link
   
Date: 3/2011

Description:
Patients:
This phase 2 study involved metastatic colorectal cancer patients who were divided into two separate treatment groups. Group A consisted of 89 patients with a median age of 63 years, 70.8% of whom were male. Group B was made up of 88 patients with a median age of 62 years and 71.6% male.

Treatment:
Patients in group A were treated with the biologic agent cetuximab (a monoclonal antibody that targets cancer cells to be killed by the immune system) and the chemotherapy agents capecitabine and irinotecan.
Patients in group B were treated with cetuximab and the chemotherapy agents capecitabine and oxaliplatin.

Toxicities:
The highest level of toxicity reported for group A was of grade 4, including diarrhea, skin rash/peeling, and neutropenia.
For group B, the highest level of toxicity reported was also of grade 4, including diarrhea, skin rash/peeling, and sensory neuropathy (nerve damage).

Results:
The median progression-free survival and median overall survival for group A was 6.2 months and 21.1 months, respectively.
The median progression-free survival and median overall survival for group B was 7.1 months and 25.5 months, respectively.

Support:
This study was supported by Merck (European distributers of cetuximab, brand name Erbitux), Roche (makers of capecitabine, brand name Xeloda), and Pfizer (makers of irinotecan, brand name Camptosar).

Correspondence: Dr. Volker Heinemann; email: Volker.Heinemann@med.uni-muenchen.de

E-mail to a Friend Email Physician More Information